Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2000-01-04
2003-04-01
Ponnaluri, Padmashri (Department: 1627)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S184100, C424S193100, C546S130000, C530S389800
Reexamination Certificate
active
06541004
ABSTRACT:
BACKGROUND
Drug addiction remains a scourge of all societies, whether supplier or consumer. The predominant drugs used today are cocaine, heroin and methamphetamine in the order of their usage. There is no present antagonist for cocaine, as there is for heroin. Cocaine acts in an entirely different way from heroin in blocking the channels of the presynaptic neuron for retrieval of dopamine. Therefore, any antagonist must bind to the channel in a way which inhibits cocaine binding, while permitting the channel to retrieve the dopamine from the synaptic space. In the absence of an antagonist, other ways of responding to various hazards associated with cocaine are necessary.
There have been recent reports that a vaccine against cocaine is being developed, which is the subject matter of WO96/30049. Also, there has been a report that a compound has been found which binds to the dopamine channel without closing the channel and inhibits the action of cocaine. However, these efforts are in the early stages of development and may never demonstrate efficacy in patients and drug addicts.
Cocaine is known to be rapidly metabolized to benzoylecgonine, which is believed to be physiologically inactive. Furthermore, cocaine becomes rapidly distributed in the various compartments of the body and can provide a rush in less than a minute, depending upon the method of administration. It is known that if one imbibes alcohol when taking cocaine, there is a rapid transesterification to the ethyl ester called “cocaethylene.” Cocaethylene is known to retain efficacy longer.
In the absence of a specific antagonist, the treatment for cocaine overdose is to sedate the patient and provide drugs to ameliorate the bradycardia. Therefore, during the time that it is important for the doctor to communicate with the patient, the patient is comatose. Since cocaine appears to be able to distribute itself rapidly into different compartments, the ability to remove the cocaine from the blood, should also result in reducing the amount of cocaine in the brain and heart. However, there are uncertainties with the use of antibodies to sequester cocaine in the blood as part of the treatment of cocaine overdose, in that antibodies have a much larger molecular weight than cocaine and the amount of antibody required for efficacy could be prohibitive, both physiologically and economically, the therapeutic response is uncertain, the average dose of cocaine in the case of overdose is not known and the antibodies should be able to bind to whatever active compound is present in the blood, while not binding to physiologically inactive compounds.
SUMMARY OF THE INVENTION
Novel compositions are provided based on the ethyl ester of benzoylecgonine or its amide analog. Linking groups are bonded to the benzoyl group for conjugation to a T cell epitope for immunization of mammals for the production of antisera which specifically binds to cocaine and cocaethylene, while having a low affinity to benzoylecgonine. The B cells from the mammalian host may be used to produce monoclonal antibodies having the same specificity spectrum. The antisera and monoclonal antibodies may be used in assays for intact cocaine and cocaethylene, for treatment of cocaine overdose, in cocaine detoxification, vaccination and in other applications associated with cocaine and its ethyl analog.
REFERENCES:
patent: 3888866 (1975-06-01), Leute et al.
patent: 3917582 (1975-11-01), Soffer et al.
patent: 4045420 (1977-08-01), Soffer et al.
patent: 4375414 (1983-03-01), Strahilevitz
patent: 4620977 (1986-11-01), Strahilevitz
patent: 4813924 (1989-03-01), Strahilevitz
patent: 4834973 (1989-05-01), Strahilevitz
patent: 5037645 (1991-08-01), Strahilevitz
patent: 5202270 (1993-04-01), Ungemach et al.
patent: 5302703 (1994-04-01), Buechler et al.
patent: 5474772 (1995-12-01), Maddock
patent: 5643732 (1997-07-01), Strahilevitz
patent: 5677132 (1997-10-01), Strahilevitz
patent: 5760184 (1998-06-01), Swain et al.
patent: 5817770 (1998-10-01), Scherrmann et al.
patent: 5840307 (1998-11-01), Swain et al.
patent: 5840588 (1998-11-01), Strahilevitz
patent: 5876727 (1999-03-01), Swain et al.
patent: 6114508 (2000-09-01), Scherrmann et al.
patent: 0467783 (1992-01-01), None
patent: 0475783 (1992-03-01), None
patent: WO 91/19980 (1991-12-01), None
patent: WO 93/12111 (1993-06-01), None
patent: WO 96/30049 (1996-10-01), None
Oyler et al (Oct. 1996)Analytical Toxicology20:6:453-62.
Galons Herve
Pouletty Philippe
Scherrmann Jean-Michel
DrugAbuse Sciences, Inc.
Ponnaluri Padmashri
Rae-Venter Barbara
Rae-Venter Law Group
LandOfFree
Cocaethylene immunogens and antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cocaethylene immunogens and antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cocaethylene immunogens and antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3076869